Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix…
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN)BPDCN…
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering November 24, 2025…
November 21, 2025 16:30 ET | Source: Olema Oncology SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”,…
Accelerating Oncology Therapeutics and Revolutionizing Operations through Intelligent, AI-Powered Frontline Solutions HYDERABAD, India, Nov. 13, 2025 /PRNewswire/ -- WinWire today…
Updated cancer treatment guidelines reflect significant progress in cancer care delivery through ongoing collaborative efforts to strengthen oncology resources across…
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…
October 24, 2025 07:02 ET | Source: Kura Oncology, Inc. - Milestone triggered by dosing of first patient in frontline…
Florricks Lifecare Private Limited, a leading research-driven global pharmaceutical company renowned for its innovative R&D, production, and sales of Active…
Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…